Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

Journal of Investigative Dermatology

Volumn 137, Issue 8, 2017, Pages 1740-1748

  Kim, Sun Hye ^a   Li, Man ^a   Trousil, Sebastian ^a   Zhang, Yaqing ^b   Pasca di Magliano, Marina ^b   Swanson, Kenneth D ^c   Zheng, Bin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PD 1 ANTIBODY; PHENFORMIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN ANTIBODY; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; PDCD1 PROTEIN, MOUSE; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MELANOMA; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS, EXPERIMENTAL; PHENFORMIN; PROGRAMMED CELL DEATH 1 RECEPTOR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 85024881255     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2017.03.033     Document Type: Article

References (23)

1. Blagih, J., Coulombe, F., Vincent, E.E., Dupuy, F., Galicia-Vázquez, G., Yurchenko, E., et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42 (2015), 41–54.
2. Bridges, H.R., Jones, A.J.Y., Pollak, M.N., Hirst, J., Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462 (2014), 475–487.
3. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr., et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41 (2009), 544–552.
4. Draghiciu, O., Lubbers, J., Nijman, H.W., Daemen, T., Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology, 4(1), 2015, e954829.
5. Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., Udono, H., Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 112 (2015), 1809–1814.
6. Hardie, D.G., Schaffer, B.E., Brunet, A., AMPK: An energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol 26 (2015), 190–201.
7. Martens, A., Wistuba-Hamprecht, K., Geukes Foppen, M., Yuan, J., Postow, M.A., Wong, P., et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22 (2016), 2908–2918.
8. Marvel, D., Gabrilovich, D.I., Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125 (2015), 3356–3364.
9. Morales, D.R., Morris, A.D., Metformin in cancer treatment and prevention. Annu Rev Med 66 (2015), 17–29.
10. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111 (2008), 4233–4244.
11. Pearce, E.L., Walsh, M.C., Cejas, P.J., Harms, G.M., Shen, H., Wang, L.-S., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460:7251 (2009), 103–107.
12. Pollak, M., Potential applications for biguanides in oncology. J Clin Invest 123 (2013), 3693–3700.
13. Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., et al. Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res 22 (2016), 5661–5672.
14. Shackelford, D.B., Abt, E., Gerken, L., Vasquez, D.S., Seki, A., Leblanc, M., et al. LKB1 Inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23 (2013), 143–158.
15. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
16. Shen, C.-H., Yuan, P., Perez-Lorenzo, R., Zhang, Y., Lee, S.X., Ou, Y., et al. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell 52 (2013), 161–172.
17. Thevenot, P.T., Sierra, R.A., Raber, P.L., Al-Khami, A.A., Trillo-Tinoco, J., Zarreii, P., et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41 (2014), 389–401.
18. Trousil, S., Chen, S., Mu, C., Shaw, F.M., Yao, Z., Ran, Y., et al. Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma. J Invest Dermatol 137 (2017), 1135–1143.
19. Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res 4 (2016), 345–353.
20. Wheaton, W.W., Weinberg, S.E., Hamanaka, R.B., Soberanes, S., Sullivan, L.B., Anso, E., et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife, 3, 2014 e02242–2.
21. Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J.H., Shen, C.-H., et al. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci USA 110:45 (2013), 18226–18231.
22. Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells on tumor bearing mice. J Immunol 181 (2008), 5791–5802.
23. Zheng, B., Jeong, J.H., Asara, J.M., Yuan, Y.-Y., Granter, S.R., Chin, L., et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33 (2009), 237–247.